I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP)

R. Matsunuma, Y. Ohkuni, K. Nakashima, K. Ando, T. Iwasaki, N. Asai, D. Yasui, M. Misawa, N. Kaneko (Kamogawa City, Japan)

Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Matsunuma, Y. Ohkuni, K. Nakashima, K. Ando, T. Iwasaki, N. Asai, D. Yasui, M. Misawa, N. Kaneko (Kamogawa City, Japan). I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP). Eur Respir J 2010; 36: Suppl. 54, 4939

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010

Validation of a computer predictive model to stratify risk and site of care in community acquired pneumonia (CAP)
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005


Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012


Prevalence of hyponatremia (HN) in children with community acquired pneumonia (CAP) and its relation to disease severity, outcomes
Source: Virtual Congress 2021 – Acute paediatric respiratory infections
Year: 2021


Factors related to obtain an etiological diagnosis in community acquired pneumonia (CAP)
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007



Progress of quality indicator rates regarding treatment of patients hospitalized in Germany due to community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010

The pneumonia severity index (PSI) do not underestimate the severity of community-acquired pneumonia (CAP) in young patients: results from the CAPO international study
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008


Acute respiratory failure (ARF) and severe sepsis (SS) in community acquired pneumonia (CAP): different outcomes?
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009


Biological markers in hospitalised patients with community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010

Severity assessment of community acquired pneumonia (CAP) using guidelines and prediction rule
Source: Eur Respir J 2002; 20: Suppl. 38, 443s
Year: 2002

Biomarkers to discriminate bacterial, viral and mixed community acquired pneumonia (CAP)
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


A prospective comparison of nursing home acquired pneumonia (NAP) with community acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 257s
Year: 2005

Defining stability in pneumonia and the non-responding pneumonia
Source: Annual Congress 2005 - Outcome in severe pneumonia
Year: 2005

Community acquired pneumonia (CAP) mortality and biomarkers
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Clinical stability in patients with community- acquired pneumonia (CAP)
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011

Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP)
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015


Community acquired pneumonia (CAP). Mortality prediction using the BTS-rule
Source: Eur Respir J 2004; 24: Suppl. 48, 413s
Year: 2004

Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 641s
Year: 2005

Determination of community acquired pneumonia (CAP) severity in pregnant (pr.)
Source: Virtual Congress 2021 – Clinical features and challenges of COVID-19
Year: 2021